Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Exploring the link between immunoglobulin deficiency and fatigue in multiple sclerosis patients

Official title: Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? - A Prospective Observational Fatigue Trial

Run by Insel Gruppe AG, University Hospital Bern · NCT05357781 · Data updated 2026-11-12

This study is trying to see if low levels of a certain antibody in people with multiple sclerosis can be a cause of their fatigue and if treating it could help them feel better.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment106 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Drugs / interventionsimmunotherapy
Locations1 site (Bern, Canton of Bern)
StatusRecruiting
StartedJuly 1, 2022
Main results expectedDecember 30, 2026
Study endsDecember 30, 2026
Registry record updatedMay 1, 2026
Trial IDNCT05357781 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18-65 with a stable diagnosis of multiple sclerosis and no significant psychiatric or immunodeficiency issues.

Probably not a fit

Patients with severe depression, other forms of immunodeficiency, or those already receiving immunoglobulin replacement therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate whether hypogammaglobulinemia, characterized by low IgG serum levels, is a treatable cause of fatigue in patients with multiple sclerosis (MS). The primary objective is to establish a connection between hypogammaglobulinemia and fatigue, while the secondary objective focuses on understanding if fatigue is exacerbated by frequent infections in these patients. The study will involve laboratory tests to assess immunoglobulin levels in individuals diagnosed with MS who meet specific inclusion criteria. By identifying potential treatable factors contributing to fatigue, the study seeks to improve the quality of life for MS patients.

Why it matters

Potential benefit: If successful, this study could lead to new treatment options for fatigue in multiple sclerosis patients by addressing underlying immunoglobulin deficiencies.

How similar studies have gone: While studies have shown correlations between immunoglobulin therapy and fatigue in other conditions, this specific approach in multiple sclerosis is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Diagnosis of Multiple Sclerosis following McDonald 2017-Criteria
* Age 18-65 years
* Stable MS disease at inclusion (definition: no clinical relapse, no MRI activity, stable disability within the last 12 months)
* Unchanged immunotherapy within the last 12 months
* Expanded Disability Status Scale (EDSS) level \<4 points indicating fully ambulatory patients.
* Capability of written informed consent

Exclusion Criteria:

* Severe depression (definition: Beck Depression Index-II (BDI-II) ≥29 points) or other established psychiatric diagnosis
* Immunodeficiency other than hypogammaglobulinemia
* Immunglobulin replacement therapy or indication for immunoglobulin replacement therapy
* Severe Sleepiness (definition: Epworth-Sleepiness-Scale (ESS) \>16 points)
* Fatigue aggravating factors such: liver/renal/thyroid dysfunction, substance abuse, medication (tranquilizers /antiepileptics/psychopharmaceuticals), chronic infectious disease (like hepatitis/HIV).
* Other neurodegenerative/autoimmune disease.
* Patients not able to give written consent
* Vulnerable patients such as children, pregnant women and prisoners

Where it's running

  • University Hospital of Bern Inselspital
    Bern, Canton of Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.